Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Reem Salman

Internal Medicine Owosso, MI Medical Doctor

NPI 1972530046 CMS profile 89519

300 Health Park Dr., Suite 304, Owosso, MI 48867

Open in the dashboard

General payments

$5,462

321 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Reem Salman of Owosso, MI is reported in the CMS Open Payments database as having received $5,462 across 321 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,027 49
2024 General $1,223 68
2023 General $616 35
2022 General $310 17
2021 General $716 45
2020 General $537 35
2019 General $1,034 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Reem Salman
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Reem Salman were reported at $1,027. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Reem Salman Internal Medicine median Middle half National median
2019 $1,034 $159 $48–$570 $163
2020 $537 $119 $33–$402 $114
2021 $716 $135 $37–$521 $132
2022 $310 $141 $42–$496 $149
2023 $616 $149 $45–$519 $160
2024 $1,223 $154 $47–$537 $164
2025 $1,027 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $869 47 payments
  2. Pfizer Inc. $648 46 payments
  3. Novo Nordisk Inc $583 34 payments
  4. GlaxoSmithKline, LLC. $377 26 payments
  5. Astellas Pharma US Inc $344 14 payments
  6. AbbVie, Inc. $258 18 payments
  7. Amgen Inc. $253 17 payments
  8. Merck Sharp & Dohme Corporation $228 18 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $221 11 payments
  10. Lilly USA, LLC $192 12 payments
  11. Other $1,490 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,302 319 payments
  2. Education $160 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $485 28 payments
  2. RYBELSUS $433 24 payments
  3. FARXIGA $345 13 payments
  4. TRELEGY ELLIPTA $344 24 payments
  5. ELIQUIS $321 22 payments
  6. BREZTRI $292 9 payments
  7. AIRSUPRA $286 12 payments
  8. PREVNAR 20 $251 18 payments
  9. SYMBICORT $244 15 payments
  10. COMIRNATY $238 17 payments
  11. Other $5,095 318 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 80 drugs

Part D claims

2,782

Median for Pediatric Medicine: 38

Drug cost

$235,008

Median for Pediatric Medicine: $2,769

Branded share of claims

21.4%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 64 $76,506
Jardiance Empagliflozin Brand 28 $37,402
Eliquis Apixaban Brand 25 $34,280
Farxiga Dapagliflozin Propanediol Brand 25 $17,850
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $13,968
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 11 $6,748
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 15 $4,872
Potassium Chloride Generic 43 $2,501
Raloxifene Hcl Generic 44 $2,062
Synthroid Levothyroxine Sodium Brand 26 $1,963

The 10 drugs with the highest cost, of 80 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$41,325

Of which drugs: $9,155

Medicare patients

75

Average age 72

Services billed

573

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Osteoporosis 29%
Chronic kidney disease 27%
Depression 27%
Diabetes 25%
Atrial fibrillation 19%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 16 16 $4,627
Vaccine for influenza for injection into muscle 90662 Office 27 27 $2,209
Sarscv2 vac 30mcg trs-suc im 91320 Office 13 13 $1,962

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $117
  • Lilly USA, LLC $33
$151 28 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $116
$116 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $107
$107 12 —
VRAYLAR
  • AbbVie, Inc. $90
$90 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

321 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record